Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.
Clinical trial NCT07339553 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07339553
- Sponsor
- Peking University Third Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-04
- Primary completion
- 2029-01-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.